Shotaro Tachibana

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Eugenio Mercuri, Francesco Muntoni, Giovanni Baranello et al. · The Lancet Neurology · 2021 · 256 citations

Medicine, Neurology, Neuroscience +12

Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

Riccardo Masson, Maria Mazurkiewicz-Bełdzińska, Kristy Rose et al. · The Lancet Neurology · 2022 · 104 citations · Full text

Medicine, Neurology, Pharmacotherapy +6

Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

Kosuke Ebina, Yuki Etani, Yuichi Maeda et al. · RMD Open · 2023 · 26 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study

Ryu Watanabe, Kosuke Ebina, Takaho Gon et al. · Lara D. Veeken · 2024 · 24 citations

Medicine, Internal Medicine, Pharmacotherapy +15

Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

Shinya Hayashi, Shotaro Tachibana, Toshihisa Maeda et al. · Lara D. Veeken · 2023 · 23 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17